Table 2 CMR finding in ESRD patients suffered and free of HF

 EF (%)

64.99 ± 4.43

58.10 ± 6.99^a

45.77 ± 17.04^a,b

 EDV (ml)

116.45 ± 31.32

122.22 ± 32.25

155.08 ± 63.04^a

 ESV (ml)

42.07 ± 9.14

52.05 ± 16.86

92.58 ± 70.56^a,b

 SV (ml)

78.65 ± 16.60

69.84 ± 19.17

61.73 ± 19.52^a,b

 Mass(g)

51.79 ± 17.31

84.63 ± 31.75

95.03 ± 29.95^a,b

 GRS (%)

43.13 ± 10.66

43.40 ± 14.74

31.89 ± 16.20^a,b

 GCS (%)^a

−18.61 (−20.25, −16.90)

−18.91 (− 20.92, − 16.70)

−17.10 (− 19.04, − 12.31)^a,b

 GLS (%)

−16.68 ± 2.90

−15.99 ± 3.36

−12.96 ± 4.98^a,b

 Non-presence (n, %)

N/A

2 (5.00%)

0

 Patchy (n, %)

N/A

17 (42.50%)

7 (26.92%)

 Diffused (n, %)

N/A

21 (52.50%)

19 (73.08%)

 Total enhanced volume>5SD(ml)

N/A

14.62 ± 12.79

23.13 ± 13.10^b

 LGE Extent>5SD(%)

N/A

13.92 ± 12.18

22.04 ± 12.47^b

 Native T1 values (ms)

1276.35 ± 56.56

1319.39 ± 55.44^a

1360.10 ± 50.14^a,b

 Post-contrast T1 values (ms)

502.91 ± 30.76

497..74 ± 74.24

510.24 ± 71.21

 λ (%)

49.79 ± 3.79

48.80 ± 5.81^a

51.06 ± 6.24^a,b

 ECV (%)

26.97 ± 1.87

31.85 ± 3.01^a

35.42 ± 4.42^a,b